Kronos Bio Inc. (KRON): Price and Financial Metrics
GET POWR RATINGS... FREE!
KRON Stock Price Chart Interactive Chart >
KRON Price/Volume Stats
| Current price | $3.69 | 52-week high | $28.42 |
| Prev. close | $3.41 | 52-week low | $3.21 |
| Day low | $3.35 | Volume | 605,200 |
| Day high | $3.73 | Avg. volume | 372,018 |
| 50-day MA | $5.57 | Dividend yield | N/A |
| 200-day MA | $12.35 | Market Cap | 209.34M |
Kronos Bio Inc. (KRON) Company Bio
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Latest KRON News From Around the Web
Below are the latest news stories about Kronos Bio Inc that investors may wish to consider to help them evaluate KRON as an investment opportunity.
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial ResultsPhase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib trial to start in Q1 2022; Phase 3 registrational AGILITY trial of entospletinib underway, with results anticipated in the second half of 2023 $339.5 million in cash, cash equivalents and investments as of December 31, 2021, providing expected runway into the second half of 2024 SAN MATEO, Calif. and CA |
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical DevelopmentSAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development. Dr. Olek joins Kronos Bio from Loxo Oncology at Lilly. Dr. Olek will be responsible for the planning, conduct and analysis of Kronos Bio’s clinical trials, reporting to Jorge DiMa |
We're Not Very Worried About Kronos Bio's (NASDAQ:KRON) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00Kronos Bio, Inc. (NASDAQ:KRON) shares gapped down before the market opened on Tuesday . The stock had previously closed at $14.00, but opened at $13.70. Kronos Bio shares last traded at $14.66, with a volume of 1,131 shares trading hands. Several analysts recently commented on KRON shares. Zacks Investment Research raised Kronos Bio from a […] The post Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00 appeared first on ETF Daily News . |
Kronos Bio, Inc. (NASDAQ:KRON) VP Sells $202,892.74 in StockKronos Bio, Inc. (NASDAQ:KRON) VP Jorge Dimartino sold 16,402 shares of the firms stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $12.37, for a total value of $202,892.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through [] |
KRON Price Returns
| 1-mo | -25.45% |
| 3-mo | -50.60% |
| 6-mo | -68.13% |
| 1-year | -84.88% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -72.85% |
| 2021 | -54.50% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...